prolonged exposure Stage 5 - confined to bed and wheelchair
MOVEMENT DISORDERS MPTP – synthetic heroin causing severe and
permanent parkinsonism Unified Parkinson’s Disease Rating Scale (UPDRS) (CNS) Drug-Induced – thought to interfere c dopaminergic mechanisms Primary Motor Symptoms Related Anatomy: Basal Ganglia o Neuroleptics Rigidity – increased resistance to passive motion Parts o Antidepressants Cogwheel – jerky, ratchet-like resistance Caudate o Antihypertensive o Tremor coexists with rigidity Putamen Reserpine – heart Lead pipe – sustained resistance to passive Globus Pallidus Metabolic Conditions – disorders of calcium movement with no fluctuations Subthalamic Nucleus metabolism Bradykinesia – slowness of movement Substantia nigra Hypothyroidism o Insufficient recruitment of muscle force Substantia Nigra pars compacta – releases dopamine, Hyper/hypoparathyroidism during initiation modulating impulses Wilson’s Disease – liver o Bradyphrenia – slowness of thought Deficiency of dopamine Parkinsonism-plus Syndromes o Akinesia – poverty of spontaneous Direct motor loop – excitatory May present c rigidity and bradykinesia movement (akinetic mutism) Cortex (Areas 4 & 6) Striatum synapse in GPi indistinguishable from PD o Hypomimia – masked facial expression Thalamus Cortex Symptoms typically do not show measurable Tremor – involuntary shaking/oscillating movement Indirect loop – decreases thalamocortical activation improvement from administration of anti- d/t contraction of opposing muscles Cortex Striatum GPe Subthalamic nucleus Parkinson medications Resting Tremor – suppressed briefly by GPi Thalamus Cortex Pathophysiology voluntary movement, disappears with sleep Degeneration of dopaminergic neurons in the BG in the Aggravated by emotional stress/excitement Parkinsonism – primary disturbance in the dopamine pars compacta presence of Lewy bodies Pill rolling tremor – specific type present in systems of the BG (cytoplasmic inclusion bodies) clinical symptoms @ persons with Parkinsonism 30-60% degeneration of neurons Postural Instability Parkinson’s Disease (Idiopathic/Primary Parkinsonism) Stages: Festinating gait pattern – both forward and “Shaking palsy” by James Parkinson, 1817 Stage 1 – medulla oblongata (intermediate reticular backward walking (anteropulsive) Two distinct clinical subgroups zones) o Postural instability gait disturbed Stage 2 – involves caudal raphe nuclei, gigantocellular Nonmotor o Tremor predominant reticular nucleus, coeruleus-subcoeruleus complex Sensory Motor symptoms (Cardinal) Stage 3 – Nigrostriatal pathway Olfactory Stage 4 – cortex (temporal) Dysphagia – 95% of patients o Postural instability Stage 5 – sensory association areas of neocortex and Problem in all phases of swallowing o Tremor prefrontal areas Sialorrhea o Rigidity Stage 6 – sensory areas of neocortex and premotor Speech Disorders o Bradykinesia areas Akinetic Mutism Non-motor symptoms Cognitive Dysfunction Secondary Parkinsonism Hoehn-Yahr Classification of Disability: Dementia – loss of executive functioning Induced by external/internal factors Stage 1 – minimal/absent, unilateral if present Depression & Anxiety Post-encephalic Stage 2 – minimal bilateral/midline involvement, Encephalitis lethargica balance not impaired Autonomic Dysfunction Toxic Stage 3 – impaired righting reflexes Certain environmental toxins Stage 4 - standing and walking possible only c Manganese – m/c, hazard to miners after Assistance Pharmacologic Management – correct levels of dopamine and acetylcholine Levodopa + Carbidopa (Sinemet) – gold standard, metabolic precursor of dopamine; dopamine cannot cross the blood-brain barrier (carboxylase metabolizes L-dope into dopamine) o Given in high doses o Carbidopa – carboxylase inhibitor combined with L-Dopa to minimize needed Dopamine Agonists – enhances dopaminergic action Anticholinergic – adjunct therapy Monoamine Oxidase B Inhibitors Antiviral (Amantadine)